|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Funding for accelerating drug development initiative critical
Last week, the FDA issued its Critical Path Opportunities Report, an agenda for medical research to develop new tools to improve the current drug development “toolkit”, which, the FDA and its stakeholders agree, currently relies on technological platforms that are outdated and inefficient.
To date, the President's budget contains only modest funding (about $6 million) for Critical Path activities, and Owens worries that the FDA's ambitious initiative will flounder without an additional financial investment on the part of industry.
Identifying the 76 opportunities for improving drug development required a great effort; but even more will be needed to successfully address them. This is something that the FDA cannot accomplish by itself, (I think this is supposed to be in quotes, but it's not in the article, should we put in a “[sic]”?) warns Janet Woodcock, Chief Operations Officer at the FDA, and one of the main driving forces behind the initiative.
|home spotlight commentary research events news about contact links archives|